ARGX
$706.03
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat gener...
Recent News
Analysts Highlight Vyvgart Expansion as Major Growth Driver for Argenx (ARGX)
Argenx SE (NASDAQ:ARGX) ranks among the best growth stocks to buy and hold for the long term. Following the company’s Q4 results, Oppenheimer increased its price target for Argenx SE (NASDAQ:ARGX) to $1,060 from $1,040 on February 26 while keeping an Outperform rating. The company reported earnings per share of $8.02, exceeding the projected $5.95. […]
Deutsche Bank lifts Argenx to Buy as valuation ’no longer demanding’
Investing.com -- Deutsche Bank upgraded Argenx (EBR:ARGX) to Buy from Hold and raised its price target to €725, citing a more attractive valuation and continued commercial momentum for its key product Vyvgart despite a mixed fourth-quarter update.
Assessing Argenx (ENXTBR:ARGX) Valuation After First-Year Profitability And Positive VYVGART Phase 3 Results
argenx (ENXTBR:ARGX) has drawn fresh investor interest after reporting its first year of operating profitability and releasing positive Phase 3 VYVGART data in ocular myasthenia gravis, alongside plans for broader MG indications. See our latest analysis for argenx. Despite the strong news flow around first year profitability and positive VYVGART data, argenx’s recent share price performance has cooled. The 30 day share price return is 9.34%, while the 90 day share price return reflects a...
Argenx (ARGX) 2025 Net Product Sales Rise 90% to $4.2B as First Annual Profit Reached
Argenx SE (NASDAQ:ARGX) is one of the best NASDAQ stocks to buy according to hedge funds. On February 26, Argenx reported earnings for 2025, achieving its first year of annual operating profitability with $4.2 billion in net product sales, a 90% increase over 2024. This growth was fueled by the global adoption of VYVGART, which […]
Analysts Express Mixed Opinion on Argenx SE (ARGX) Stock
Argenx SE (NASDAQ:ARGX) is one of the 13 Most Profitable Growth Stocks to Buy Right Now. On March 2, James Gordon of Barclays maintained his Buy rating on argenx SE (NASDAQ:ARGX), along with a €900 price target. On February 27, Robert W. Baird increased its price target on argenx SE while reaffirming a Neutral rating. […]